Human Papillomavirus (HPV) Prophylaxis Landscape 2017 & Pipeline Review: Orbis Research

Latest Report on “Human Papillomavirus (HPV) Prophylaxis Landscape, 2017” is available at Orbis Research and provides Key Insights for HPV Vaccines in Healthcare Industry

Dallas, United States - July 7, 2017 /MarketersMedia/ —

Description:

‘Human PapillomaVirus (HPV) Prophylaxis Landscape, 2017’ Report provides an overview of the Human PapillomaVirus (HPV) and market trends of the Human PapillomaVirus (HPV) Vaccines in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and Rest of World (RoW).

The Report also provides in-depth analysis on the HPV Vaccines covering pre-clinical and clinical studies and Collaborations details. The Report provides the HPV vaccines licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis. The Report provides a comprehensive review of the market trends, key company profiles including its business and product developments.

Request Sample of this Report at: http://www.orbisresearch.com/contacts/request-sample/343480

The HPV vaccines have been introduced in US and most EU/EEA countries. As of May 2012, the vaccination advisory bodies in 22 of 29 countries has made a recommendation in favor of HPV vaccination, compared to 12 out of 27 countries in February 2008 in Europe. According to DelveInsight, a total of 7,288,315 people were vaccinated with HPV Vaccines in 2016 and the total number of vaccinated people with HPV Vaccine is expected to reach XXXX in 2025.

Comparative Analysis is Provided for:

• INO-3112: Inovio Pharmaceuticals, Inc.
• CKD-12201: Chong Kun Dang Pharmaceutical Corp.
• EG-HPV: EyeGene, Inc.
• iBiomodulator with the E7GGG or E7 antigens: iBio Inc.
• AX03: Agilvax
• HPV Vaccine: Soligenix
• Cervarix: GlaxoSmithKline
• Gardasil/ Gardasil 9: Merck & Co., Inc.

Browse Complete Table of Contents and Report Details at: http://www.orbisresearch.com/reports/index/human-papillomavirus-hpv-prophylaxis-landscape-2017

Total Market Size of Human PapillomaVirus (HPV) Vaccines including 6MM (the United States and EU5 countries) and RoW was estimated to be USD 1.98 Billion in 2016. The market is expected to reach a total of USD XXXX Millions by 2025 with a CAGR OF XXX% for the period 2015-2025. Market size has increased in recent years for HPV due to the approval of Gardasil 9 (Merck & Co.) which targets 9 different HPV types (Types 16, 18, 31, 33, 45, 52, and 58).

Although the overall HPV Vaccines market is increasing, the sales of Cervarix (GlaxoSmithKline) has been declining over the years owing to the company’s decision to stop the vaccines’ supply in the United States. GlaxoSmithKline has taken this step due to the low market demand of Cervarix in the US.

Key Coverage and Benefits:

• The report will help in developing business strategies by understanding the trends shaping and driving the global Human PapillomaVirus (HPV) Vaccines market.
• Organize sales and marketing efforts by identifying the best opportunities for Human PapillomaVirus (HPV) Vaccines in US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
• To understand the future market competition in the global Human PapillomaVirus (HPV) Vaccines market and Insightful review of the key market drivers and barriers.
• To understand the regulatory scenario in major markets.
• Overview of the global HPV Vaccines pipeline scenario, products and associated companies information.

Check for Discount on Report Purchase at: http://www.orbisresearch.com/contacts/discount/343480

Coverage of Global HPV Vaccines under development.

Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities.
The Report also covers the detailed global historical and forecasted Human PapillomaVirus (HPV) Vaccines market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025.

Points Covered in Table of Contents:

Executive Summary
Human PapillomaVirus (HPV) Vaccines Market Overview at a Glance
7 MM and ROW Market Size of Human PapillomaVirus (HPV) Vaccines (2015-2025)
Total Market Share Distribution of Human PapillomaVirus (HPV) Vaccines for 7 MM in 2016
Total Market Share Distribution of Human PapillomaVirus (HPV) Vaccines for 7 MM in 2025
Human papillomavirus (HPV)
Categories of Human papillomavirus (HPV)
Causes
Cancers caused by HPV
The HPV vaccination
… and Continued

Enquire more about Report at: http://www.orbisresearch.com/contacts/enquiry-before-buying/343480

Contact Info:
Name: Hector Costello
Email: [email protected]
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600,

Source URL: http://marketersmedia.com/human-papillomavirus-hpv-prophylaxis-landscape-2017-pipeline-review-orbis-research/215433

For more information, please visit http://www.orbisresearch.com/reports/index/human-papillomavirus-hpv-prophylaxis-landscape-2017

Source: MarketersMedia

Release ID: 215433